Evaluation of the Rigicon Infla10® Inflatable Penile Prosthesis (IPP) for Erectile Dysfunction

Official title

Evaluation of the Rigicon Infla10® Inflatable Penile Prosthesis (IPP) A Prospective, Multicenter, Single-Arm Performance-Goal Study

Overview

This study evaluates the long-term safety and effectiveness of the Rigicon Infla10® Inflatable Penile Prosthesis in patients with erectile dysfunction. The study follows patients implanted with the Rigicon Infla10® Pulse™ Dynamic Inflatable Penile Prosthesis for up to 3 years after implantation.

Detailed description

Erectile dysfunction (ED) is a common male sexual dysfunction associated with a reduced quality of life for patients and their partners. Incidence of ED increases with age and is associated with depression, obesity, diabetes mellitus, hypertension, cardiovascular disease and benign prostatic hyperplasia. ED is diagnosed with symptoms of (1) inability to attain or sustain a penile erection during sexual activity and (2) a reduction of penile rigidity in \>75% of sexual encounters during six months period. ED is estimated to affect approximately 52% of men in age of 40 to 70 years. It is projected in 2025, the worldwide ED prevalence of about 322 million. ED usually has organic causes, such as damage of arteries, smooth muscle and fibrous tissue. This results in impairment of blood flow to and from penis due to diabetes, renal disease, atherosclerosis and vascular disease.

Management of ED involves lifestyle modification, medical, surgical interventions, and possibly, in the future, tissue- engineering or cellular or gene therapy. Oral phosphodiesterase type 5 inhibitor (PDE5i), which works with sexual stimulation, is an effective medical therapy for ED with an excellent safety profile. Intracavernosal injection or topical application of vasoactive drugs have also been studied. The first inflatable penile prosthesis was introduced in 1973, and current models of inflatable penile prostheses include the AMS 700 series, Coloplast Titan device and Zephyr ZSI device. A patient-activated inflatable penile prosthesis (IPP) provides patients with a means to achieve dependable spontaneity for intercourse.

Rigicon has developed a three-piece inflatable penile prosthesis (IPP) (Infla10®) for the treatment of ED. This study is to assess the safety and effectiveness of the Rigicon IPP in treating ED. Clinical literature and preclinical testing, including biocompatibility, device validation and verification, and animal studies support the safety and efficacy of this device for the intended therapy.

Interventions

• Device Rigicon Infla10® Inflatable Penile Prosthesis (IPP)
  Medical Device: Infla10® Pulse™ Dynamic Inflatable Penile Prosthesis • Other Names: Inflatable Penile Prosthesis (IPP) Treatment: Erectile dysfunction

Primary outcome measures

• The primary safety outcome is the proportion of participants free from any device- or procedure-related adverse event of CTCAE Grade ≥2 through 12 months post-procedure, graded per CTCAE v5.0 and IPP-specific mapping. [Time frame: 12 months]
• The primary effectiveness endpoint is a binary "pass" or "fail" objective axial rigidity test, assessed at 12 months. [Time frame: 12 months]

Secondary outcome measures (4)

• Percentage of patients free from revision or explant surgeries at 12 months. [Time frame: 12 months]
• International Index of Erectile Function - Erectile Function (IIEF-EF) Domain Score [Time frame: Baseline (pre-implantation) and Months 3, 6, 12, 18, 24, and 36 post-implantation.]
• Rosenberg Self-Esteem Scale (RSES) Total Score [Time frame: Baseline (pre-implantation) and Months 3, 6, 12, 18, 24, and 36 post-implantation.]
• Adverse Events [Time frame: 36 months]

Eligibility criteria

Inclusion criteria

• Male ≥22 years of age.
• Diagnosed with erectile dysfunction (impotence).
• Agree to receive Infla10® three-piece IPP as an ED treatment.
• Willing to complete all protocol required for follow-up visits and tests.

Exclusion criteria

• Contraindication to general anesthesia.
• Known allergy or sensitivity to product materials as indicated in the device labeling.
• Previous penile prosthesis or prior enlargement surgeries
• Diagnosed penile sensory neuropathy.
• Patients who are receiving immunosuppressive drugs or have a history of kidney transplantation.
• Patients who are receiving chemotherapy at the time of enrolment.
• Diagnosed with fibrotic disease, such as priapism or Peyronie's disease or Chordee.
• Compromised immune system, such as systemic lupus erythematosus, discoid lupus, or scleroderma.
• Uncontrolled diabetes (HbA1c ≥ 9.0% \[≈75 mmol/mol\], measured within 90 days prior to surgery.
• Bleeding disorder or coagulopathy that may in the judgment of the investigator preclude safe procedure.
• Active urogenital infection or active skin infection in region of surgery or systemic infection at the time of assessment.
• Clinically significant comorbidities or presence of unstable conditions (e.g. cardiovascular, lung, renal \[serum creatinine > 2.0 mg/dl\], hepatic, bleeding disorders, or metabolic impairment) that may confound the results of the study or in the judgment of the physician investigator preclude safe procedure.
• Lacking manual dexterity or mental abilities necessary to operate the device.
• Expected life expectancy < two years.
• Unwilling or unable to sign the Informed Consent.
• Unwilling or unable to comply with the follow-up study requirements.
• Psychogenic erectile dysfunction
• Currently participating in an investigational drug or another investigational device exemption (IDE) study.
• The cognitively challenged subjects and subjects with any cognitive disorder that interferes with or precludes direct and accurate communication with the study investigator regarding the study or affects the ability to complete the study questionnaires.
• Incarcerated subjects
• Subjects who are currently using, or who have not previously attempted and failed, standard non-surgical ED therapies including oral or topical treatments.

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Allocation

N/A

Model

Single group

Masking

Open label

Primary purpose

Treatment

Study locations

United States · 7 centers

• Perito Urology — Coral Gables
• Atlanta Cosmetic Urology — Atlanta
• UroPartners — Chicago
• Kramer Urology — Hyannis
• Washington Heights Urology — New York
• Urology Partners of North Texas — Arlington
• Vitality Urology Institute — Houston

Identifiers

NCT: NCT07273773 · RC2025_UNITED

Primary sources (government registries)

• ClinicalTrials.gov (US NIH)

View this study on ClinicalTrials.gov ↗